These observations have led to the concept of an “inflamed-depression” subtype, in which elevated C-reactive protein or interleukin-6 predicts poorer SSRI response yet may identify patients who benefit from alternative agents or anti-inflammatory augmentation [70, 71]. This evidence concerns the gene IL6 and major depressive disorder.